ALS (Motor Neurone Disease) stem cell therapy — your questions answered (2026)

About stem cell therapy for ALS (Motor Neurone Disease)

Amyotrophic lateral sclerosis (ALS or motor neurone disease) is a neurodegenerative condition characterised by progressive loss of motor neurons in the spinal cord, brainstem and motor cortex. Multiple mechanisms are under investigation, including excitotoxicity, mitochondrial dysfunction, protein misfolding and neuroinflammation. Neural progenitor and mesenchymal stromal cell approaches are being studied for proposed neuroprotective or supportive effects, but these mechanisms have not established slowed progression or restored motor function in people. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for ALS (Motor Neurone Disease)

Human ALS cell-therapy studies are generally early-phase and heterogeneous, with different products, routes, populations and endpoints. Safety observations and exploratory biomarker changes do not establish slower functional decline or longer survival. No completed pivotal trial has established a stem-cell product as effective standard ALS treatment. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational ALS cell procedures can involve separate charges for intrathecal administration, neurological and respiratory assessment, imaging, monitoring, travel and treatment of complications. Prices do not indicate regulatory approval or expected benefit, and repeat dosing is not an established standard. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Multidisciplinary ALS care and approved or guideline-supported treatment must not be delayed.

Can stem cells treat ALS?

Cell therapy for ALS (Motor Neurone Disease) may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

What realistic goals are there?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How many sessions?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an ALS (Motor Neurone Disease) programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for ALS (Motor Neurone Disease) (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to ALS (Motor Neurone Disease) overview · ALS (Motor Neurone Disease) cost →